Lenalidomide and its role in the management of multiple myeloma

Patrizia Falco, Federica Cavallo, Alessandra Larocca, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review


Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.

Original languageEnglish
Pages (from-to)865-874
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number6
Publication statusPublished - 2008


  • Combination therapy
  • Lenalidomide
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology


Dive into the research topics of 'Lenalidomide and its role in the management of multiple myeloma'. Together they form a unique fingerprint.

Cite this